HER2 phosphorylation induced by TGF-β promotes mammary morphogenesis and breast cancer progression.
Qiaoni ShiFei HuangYalong WangHuidong LiuHaiteng DengYe-Guang ChenPublished in: The Journal of cell biology (2024)
Transforming growth factor β (TGF-β) and HER2 signaling collaborate to promote breast cancer progression. However, their molecular interplay is largely unclear. TGF-β can activate mitogen-activated protein kinase (MAPK) and AKT, but the underlying mechanism is not fully understood. In this study, we report that TGF-β enhances HER2 activation, leading to the activation of MAPK and AKT. This process depends on the TGF-β type I receptor TβRI kinase activity. TβRI phosphorylates HER2 at Ser779, promoting Y1248 phosphorylation and HER2 activation. Mice with HER2 S779A mutation display impaired mammary morphogenesis, reduced ductal elongation, and branching. Furthermore, wild-type HER2, but not S779A mutant, promotes TGF-β-induced epithelial-mesenchymal transition, cell migration, and lung metastasis of breast cells. Increased HER2 S779 phosphorylation is observed in human breast cancers and positively correlated with the activation of HER2, MAPK, and AKT. Our findings demonstrate the crucial role of TGF-β-induced S779 phosphorylation in HER2 activation, mammary gland development, and the pro-oncogenic function of TGF-β in breast cancer progression.
Keyphrases
- transforming growth factor
- epithelial mesenchymal transition
- signaling pathway
- protein kinase
- induced apoptosis
- wild type
- cell migration
- oxidative stress
- pi k akt
- endothelial cells
- type diabetes
- transcription factor
- single molecule
- cell death
- adipose tissue
- endoplasmic reticulum stress
- diabetic rats
- metabolic syndrome
- binding protein
- breast cancer risk